China multicenter study of sentinel node biopsy substituting axillary node dissection: CBCSG-01 trial

Wang, Y.S.; Ouyang, Tao; Wang, Q.T.; Su, Fengtao; Zhu, Shijie; Wu, Jiarui; Yu, C.Z.; Cao, Siyang; Wang, S.; Li, J.Y.

doi:10.1016/s1359-6349(08)70719-5

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients enrolled in the study were ≥18 years of age with a diagnosis of early breast cancer and scheduled for a SLNB. Patients who had undergone previous ipsilateral axillary surgery were excluded from the study (4).…”

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences

Sun

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The axillary treatment of patients with ductal carcinoma in situ (DCIS) remains controversial. The aim of the present study was to evaluate the roles of sentinel lymph node biopsy (SLNB) in patients with breast DCIS. A database containing the data from 262 patients diagnosed with breast DCIS and 100 patients diagnosed with DCIS with microinvasion (DCISM) who received SLNB between January 2002 and July 2014 was retrospectively analyzed. Of the 262 patients with DCIS, 9 presented with SLN metastases (3 macrometastases and 6 micrometastases).Patients with large tumors diagnosed by ultrasound or with tumors of high histological grade had a higher positive rate of SLNs than those without (P=0.037 and P<0.0001, respectively). Of the 100 patients with DCISM, 11 presented with metastases. Younger patients had a higher positive rate of SLNs (P=0.028). According to the results of this study and the systematic review of recent studies, the indications of SLNB for patients with DCIS are as follows: SLNB should be performed in all DCISM patients and in those DCIS patients who received mastectomy, and could be avoided in those who received breast-conserving surgery. However, SLNB should be recommended to patients who have high risks of harboring invasive components. The risk factors include a large, palpable tumor, a mammographic mass or a high histological grade.

show abstract

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences

Sun

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…[ 3 , 4 , 34 ] Surgeons should be trained to reduce the SLNB clinical false-negative rate associated with surgical procedures. [ 63 ] In clinical practice in China, intraoperative frozen section pathological examination is the main pathological evaluation in SLNB intra-operatively, with a reported false-negative rate of approximately 10%. [ 64 ] Currently, the expert panel believes that the frozen section pathological assessment of SLNs is appropriate in China, and suggests that we should strictly implement specimen sampling and standardize pathological reporting processes according to the standards of the College of American Pathologists [ 43 ] to reduce the pathological false-negative rate of SLNB.…”

Section: Discussionmentioning

confidence: 99%

Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Guo

Liu

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

“…Following the proposal of the Milan trial (2) in recent years, many prospective clinical trials (3)(4)(5) with large samples…”

Section: Introductionmentioning

confidence: 99%

“…However, the complications that are associated ALND, including limb lymphedema, local nerve injury, and shoulder joint dysfunction, negatively impact the patients’ quality of life ( 1 ). Following the proposal of the Milan trial ( 2 ) in recent years, many prospective clinical trials ( 3 - 5 ) with large samples have confirmed the safety and clinical practicability of sentinel lymph node biopsy (SLNB) as a replacement for ALND in patients with negative sentinel lymph nodes (SLNs). CBCSG-01 ( 5 ) prospective clinical trials revealed that patients with negative SLNs have five-year overall survival rates and disease-free survival rates of 98.2% and 94.2%, respectively.…”

Section: Introductionmentioning

confidence: 99%

“…Following the proposal of the Milan trial ( 2 ) in recent years, many prospective clinical trials ( 3 - 5 ) with large samples have confirmed the safety and clinical practicability of sentinel lymph node biopsy (SLNB) as a replacement for ALND in patients with negative sentinel lymph nodes (SLNs). CBCSG-01 ( 5 ) prospective clinical trials revealed that patients with negative SLNs have five-year overall survival rates and disease-free survival rates of 98.2% and 94.2%, respectively. NSABP B-32 ( 4 ) clinical trials showed that the overall accuracy of SLNB in patients was 97.1% and false negative (FN) rates was 9.8%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and validation of an ultrasonography and clinicopathological features-based nomogram for non-sentinel lymph node metastasis

Chen¹,

Dai²,

Chen³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

Background: With the development of precise treatment for breast cancer, the current trend of clinical treatment aims to limit axillary surgery as much as possible. At present, there is an unmet need to predict the probability of patients with a low risk of non-sentinel lymph node (SLN) metastasis and determine whether the omission of axillary lymph node dissection (ALND) is appropriate. Methods: We retrospectively analyzed the data of patients with breast cancer who underwent sentinel lymph node biopsy (SLNB) and ALND. The patients were randomly assigned to training and validation sets. The associations between non-SLN metastasis (NSLNM) and ultrasonography and clinicopathological characteristics were assessed by multivariate logistic regression. Then, a nomogram model was constructed and validated using the calibration curve and the receiver operating characteristic curve. Results: Vascular infiltration, positive SLN number, negative SLN number, human epidermal growth factor receptor 2 (HER2) status, and lymph node shape were identified as independent predictive factors for positive NSLNM. The areas under the curve of the nomogram model to predict NSLNM were 0.793 and 0.780 in the training and validation sets, respectively, and P=0.161 and P=0.768 in the Hosmer-Lemeshow goodness of fit test, respectively. Conclusions: A nomogram model based on ultrasonography and clinicopathological features predicting NSLNM was established in our study, which is helpful for accurately assessing the risk of NSLNM in invasive breast cancer and providing evidence for individual surgical procedures involving axillary lymph nodes.

show abstract

China multicenter study of sentinel node biopsy substituting axillary node dissection: CBCSG-01 trial

Cited by 4 publications

References 0 publications

Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences

Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences

Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Development and validation of an ultrasonography and clinicopathological features-based nomogram for non-sentinel lymph node metastasis

Contact Info

Product

Resources

About